Daily Cosmetic Research Analysis
Analyzed 20 papers and selected 3 impactful papers.
Summary
Analyzed 20 papers and selected 3 impactful articles.
Selected Articles
1. Efficacy and safety of ALA/MLA photodynamic therapy for superficial and nodular basal cell carcinoma: a systematic review and meta-analysis.
Across 55 studies (2123 patients), ALA/MAL-PDT achieved high complete response rates in superficial BCC (0.88) and moderate in nodular BCC (0.75), with MAL outperforming ALA in nodular disease (p=0.04). Cosmetic outcomes were excellent (≈0.90) and adverse events were generally mild; advanced formulations (BF-200 ALA, AFL-MAL) showed promising efficacy.
Impact: This synthesis clarifies subtype-specific performance of ALA versus MAL PDT and highlights newer formulations, directly informing patient-centered management that balances oncologic control with cosmetic outcomes.
Clinical Implications: Consider PDT as a first-line non-invasive option for sBCC and selected nBCC when cosmetic preservation is prioritized; prefer MAL for nBCC, and consider BF-200 ALA or AFL-MAL protocols where available. Standardize light dose and session number to reduce outcome variability.
Key Findings
- Pooled complete response for sBCC was 0.88 (95% CI 0.85–0.91) with no significant difference between ALA-PDT and MAL-PDT.
- For nBCC, pooled complete response was 0.75; MAL-PDT outperformed ALA-PDT (0.78 vs 0.69; p=0.04).
- Cosmetic outcomes were excellent (sBCC 0.91; nBCC 0.90), with low recurrence (sBCC 0.13; nBCC 0.15) and generally mild adverse events; advanced regimens (BF-200 ALA, AFL-MAL) showed higher CRs.
Methodological Strengths
- PRISMA 2020-compliant systematic review and meta-analysis
- Large aggregated sample with subgroup analyses by subtype and photosensitizer/formulation
Limitations
- High heterogeneity (I² up to 92%) and mixed study designs (RCTs and single-arm studies)
- Adverse event data for nBCC were insufficient for pooling; follow-up durations not detailed in the abstract
Future Directions: Head-to-head RCTs comparing MAL vs ALA in nBCC, standardized PDT parameters, and longer-term recurrence/cosmesis follow-up across formulations.
BACKGROUND: Basal cell carcinoma (BCC) is the most prevalent non-melanoma skin cancer, with surgical excision as the gold standard-though it carries risks of cosmetic scarring and functional impairment. Photodynamic therapy (PDT) using 5-aminolevulinic acid (ALA) or methyl aminolevulinate (MAL) emerges as a non-invasive alternative, yet evidence on its relative efficacy across superficial (sBCC) and nodular (nBCC) subtypes remains inconsistent. METHODS: This systematic review and meta-analysis adhered to PRISMA 2020 guidelines, with a comprehensive search of PubMed, Embase, Cochrane Library, and Web of Science up to December 31, 2025. Eligible studies included randomized controlled trials (RCTs) and single-arm studies evaluating ALA-PDT/MLA-PDT for histologically confirmed sBCC or nBCC. Study quality was assessed via the Methodological Index for Non-Randomized Studies (MINORS) scale, and statistical analyses were performed using Review Manager 5.4. RESULTS: A comprehensive literature search identified 3832 records, with 55 eligible studies (41 for sBCC, 34 for nBCC) ultimately included, involving 2123 patients and 2995 lesions. For sBCC, the pooled complete response (CR) rate was 0.88 (95% CI: 0.85-0.91, p<0.00001) with high heterogeneity (I²=87%); no significant difference in CR rate was observed between ALA-PDT (0.87) and MAL-PDT (0.90) (p=0.47), and BF-200 ALA-PDT achieved a CR rate of 0.90. The pooled beauty effect rate for sBCC was 0.91 (95% CI: 0.87-0.95, p<0.00001), with a low pooled adverse event incidence of 0.08 (95% CI: 0.03-0.14, p=0.004) and a pooled recurrence rate of 0.13 (95% CI: 0.09-0.18, p<0.00001). For nBCC, the pooled CR rate was 0.75 (95% CI: 0.70-0.80, p<0.00001, I²=92%), with MAL-PDT (0.78) showing a statistically significant higher CR rate than ALA-PDT (0.69) (p=0.04); BF-200 ALA-PDT and AFL-MAL-PDT achieved CR rates of 0.89 and 0.84, respectively. The pooled beauty effect rate for nBCC was 0.90 (95% CI: 0.83-0.96, p<0.00001), with a pooled recurrence rate of 0.15 (95% CI: 0.10-0.20, p<0.00001); adverse event data were insufficient for pooling, with individual studies reporting mild, manageable local reactions. Subgroup analyses revealed that study design, light dose, and number of treatment sessions were the main factors contributing to heterogeneity in key outcomes. CONCLUSIONS: ALA/MAL-PDT is an effective and safe non-invasive therapeutic option for both sBCC and nBCC, with excellent cosmetic outcomes for both subtypes. MAL-PDT exhibits significantly superior efficacy in nBCC compared with ALA-PDT, while the two photosensitizers show comparable therapeutic effects in sBCC. Novel PDT formulations including BF-200 ALA-PDT and AFL-MAL-PDT demonstrate promising CR rates for BCC, providing new treatment alternatives for clinical practice. Standardization of treatment parameters (e.g., light dose, treatment sessions) and differentiation of study design types can effectively reduce heterogeneity in PDT efficacy evaluation, and ALA/MAL-PDT should be prioritized for patients seeking minimally invasive treatment, those with multiple lesions, or those with contraindications to surgical excision.
2. EDTA suppresses bacterial perseverance to 2-phenoxyethanol.
Using time-lapse single-cell analysis, the authors investigated bacterial perseverance under cosmetic preservative stress and found that EDTA suppresses perseverance to 2-phenoxyethanol. The work underscores formulation-dependent heterogeneity and the need for single-cell approaches in preservative risk assessment.
Impact: This is among the first demonstrations of perseverance in preservative-treated bacteria and identifies a practical mitigation strategy (EDTA) relevant to cosmetic preservation and consumer safety.
Clinical Implications: Supports the use of EDTA as a preservative booster to reduce perseverance-driven failures, enabling lower preservative loads and potentially fewer irritant reactions, while maintaining product microbiological safety.
Key Findings
- EDTA suppresses the bacterial perseverance phenotype in the presence of the cosmetic preservative 2-phenoxyethanol.
- Time-lapse microscopy with a microdevice enabled single-cell quantification of division behavior under preservative stress.
- Formulation components (e.g., nutrients from plant extracts) can drive heterogeneous microbial responses, necessitating single-cell risk assessment.
Methodological Strengths
- Single-cell, time-lapse microscopy capturing phenotypic heterogeneity
- Microdevice-based platform enabling high-resolution analysis under preservative stress
Limitations
- In vitro mechanistic work; generalizability to diverse products and microbiota remains to be tested
- Focus on 2-phenoxyethanol and EDTA; broader preservative-boosters and species coverage needed
Future Directions: Extend to multiple preservatives, boosters, and microbial species in realistic formulations; evaluate long-term ecological impacts and consumer safety profiles.
Perseverance is a phenotype in which a small subpopulation of bacteria continues to divide for hours in the presence of antimicrobial concentrations that inhibit bulk population growth, without acquiring genetic resistance. Perseverance has previously been reported only in antibiotic-treated bacteria, but not in preservative-treated bacteria. However, perseverance could limit preservative efficacy, and we investigated this phenomenon in preservative-treated bacteria. Cosmetic products rely on preservatives to control microbial growth; however, preservative types and concentrations are limited for safety reasons, and boosters are often added to enhance efficacy. Some formulations also contain nutrients, such as plant extracts, that promote heterogeneous microbial behavior. Therefore, single-cell analyses are needed to understand these responses and assess preservation risk. In this study, we combined time-lapse microscopy and a microdevice to perform single-cell analysis of
3. Advancing regulatory use of NAMs for Chemical Safety Assessment: Progress in Brazil.
Brazil established a national chemical inventory via Law 15,022/2024, promotes NAMs, and restricts animal testing, culminating in a nationwide ban on cosmetic animal testing by 2025. The framework incentivizes QSAR, read-across, PBPK, and IATAs at early stages, with a 2027 horizon to align with global best practices.
Impact: This policy analysis marks a national-scale transition toward non-animal safety assessment for cosmetics and chemicals, with concrete timelines and institutional capacity-building, influencing regulatory science and industry practice.
Clinical Implications: Accelerated adoption of NAMs will shift toxicology data packages for cosmetic ingredients toward in vitro/in silico evidence, potentially expediting safer product development while upholding consumer protection.
Key Findings
- Law No. 15,022/2024 establishes the National Inventory of Chemical Substances and promotes the use of non-animal NAMs, restricting animal testing to last resort.
- Brazil’s phased ban on cosmetic animal testing started in 2023 and was fully implemented in 2025, supported by CONCEA, BraCVAM, and RENAMA.
- Early-stage registration emphasizes non-animal tools (QSAR, read-across, PBPK, IATAs), with a strategic alignment timeline toward 2027.
Methodological Strengths
- Comprehensive synthesis of legislative instruments and institutional frameworks
- Clear articulation of timelines and toolkits (QSAR, read-across, PBPK, IATAs) for implementation
Limitations
- Policy analysis without empirical outcome data on safety performance or regulatory throughput
- Implementation challenges and inter-agency harmonization are anticipated but not quantitatively assessed
Future Directions: Track performance metrics (regulatory decisions, time-to-market, safety signals) under NAMs; develop case studies for cosmetic ingredients and international harmonization protocols.
Brazil has advanced its chemical regulatory framework with the enactment of Law No. 15,022/2024, which establishes the National Inventory of Chemical Substances, aligning the country with international chemical management systems. The law creates a structured system for the registration, prioritization, and management of industrial chemicals, explicitly promoting the use of non-animal New Approach Methodologies (NAMs) and restricting animal testing to a measure of last resort. The manuscript contextualizes this new legislation within Brazil's broader regulatory and capacity-building trajectory. Starting with the Arouca Law (Law No. 11,794/2008), which established the National Council for the Control of Animal Experimentation (CONCEA), Brazil has progressively strengthened its institutional framework through the creation of BraCVAM and RENAMA. These initiatives have expanded national expertise in NAM-based testing and directly supported Brazil's phased ban on animal testing for cosmetics, initiated in 2023 and fully implemented in 2025. Brazil's model adopts a simplified, uniform data requirement at the initial registration stage, deferring more extensive data generation to the risk assessment phase. This approach incentivizes early reliance on non-animal tools such as QSAR, read-across, PBPK modeling, and IATAs. The planned timeline toward 2027 provides a strategic window to define protection goals, build regulatory confidence, and harmonize Brazil's system with global best practices, fostering ethical innovation, improved chemical safety, and sustainable industrial development.